| The MLL recombinome of acute leukemias in 2017 C Meyer, T Burmeister, D Gröger, G Tsaur, L Fechina, A Renneville, ... Leukemia 32 (2), 273-284, 2018 | 668 | 2018 |
| Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel U Creutzig, MM van Den Heuvel-Eibrink, B Gibson, MN Dworzak, ... Blood, The Journal of the American Society of Hematology 120 (16), 3187-3205, 2012 | 667 | 2012 |
| The MLL recombinome of acute leukemias in 2013 C Meyer, J Hofmann, T Burmeister, D Gröger, TS Park, M Emerenciano, ... Leukemia 27 (11), 2165-2176, 2013 | 562 | 2013 |
| Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study M Schrappe, MG Valsecchi, CR Bartram, A Schrauder, ... Blood, The Journal of the American Society of Hematology 118 (8), 2077-2084, 2011 | 509 | 2011 |
| Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study BV Balgobind, SC Raimondi, J Harbott, M Zimmermann, TA Alonzo, ... Blood, The Journal of the American Society of Hematology 114 (12), 2489-2496, 2009 | 501 | 2009 |
| Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia MN Dworzak, G Fröschl, D Printz, G Mann, U Pötschger, ... Blood, The Journal of the American Society of Hematology 99 (6), 1952-1958, 2002 | 455 | 2002 |
| Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 M Brüggemann, A Schrauder, T Raff, H Pfeifer, M Dworzak, OG Ottmann, ... Leukemia 24 (3), 521-535, 2010 | 449 | 2010 |
| Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents MW Wlodarski, S Hirabayashi, V Pastor, J Starý, H Hasle, R Masetti, ... Blood, The Journal of the American Society of Hematology 127 (11), 1387-1397, 2016 | 404 | 2016 |
| Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow G Basso, M Veltroni, MG Valsecchi, MN Dworzak, R Ratei, D Silvestri, ... Journal of clinical oncology 27 (31), 5168-5174, 2009 | 380 | 2009 |
| Collaborative efforts driving progress in pediatric acute myeloid leukemia CM Zwaan, EA Kolb, D Reinhardt, J Abrahamsson, S Adachi, R Aplenc, ... Journal of clinical oncology 33 (27), 2949, 2015 | 375 | 2015 |
| Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98 U Creutzig, M Zimmermann, D Reinhardt, M Dworzak, J Stary, ... Journal of Clinical Oncology 22 (21), 4384-4393, 2004 | 306 | 2004 |
| Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98 C Von Neuhoff, D Reinhardt, A Sander, M Zimmermann, J Bradtke, ... Journal of clinical oncology 28 (16), 2682-2689, 2010 | 290 | 2010 |
| Treatment and prognostic impact of transient leukemia in neonates with Down syndrome JH Klusmann, U Creutzig, M Zimmermann, M Dworzak, N Jorch, ... Blood, The Journal of the American Society of Hematology 111 (6), 2991-2998, 2008 | 286 | 2008 |
| Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia S Ebinger, EZ Özdemir, C Ziegenhain, S Tiedt, CC Alves, M Grunert, ... Cancer cell 30 (6), 849-862, 2016 | 268 | 2016 |
| Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group GJL Kaspers, M Zimmermann, D Reinhardt, BES Gibson, RYJ Tamminga, ... Journal of Clinical Oncology 31 (5), 599-607, 2013 | 256 | 2013 |
| AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity U Creutzig, D Reinhardt, S Diekamp, M Dworzak, J Stary, M Zimmermann Leukemia 19 (8), 1355-1360, 2005 | 239 | 2005 |
| High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia W Warsch, K Kollmann, E Eckelhart, S Fajmann, S Cerny-Reiterer, ... Blood, The Journal of the American Society of Hematology 117 (12), 3409-3420, 2011 | 237 | 2011 |
| Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. H Kovar, M Dworzak, S Strehl, E Schnell, IM Ambros, PF Ambros, ... Oncogene 5 (7), 1067-1070, 1990 | 232 | 1990 |
| Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004 U Creutzig, M Zimmermann, JP Bourquin, MN Dworzak, G Fleischhack, ... Blood, The Journal of the American Society of Hematology 122 (1), 37-43, 2013 | 216 | 2013 |
| Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML … U Creutzig, M Zimmermann, T Lehrnbecher, N Graf, J Hermann, ... Journal of clinical oncology 24 (27), 4499-4506, 2006 | 214 | 2006 |
